Clinical efficacy of recombinant activated factor Ⅶ a for 16 hematonosis with moderate or severe bleeding
10.3760/cma.j.issn.0253-2727.2017.03.008
- VernacularTitle: 重组人凝血因子Ⅶa治疗16例血液病及异基因造血干细胞移植术后合并中至重度出血患者的疗效观察
- Author:
Fan YANG
1
;
Lingjun KONG
;
Jiangwei HU
;
Na LIU
;
Yongfeng SU
;
Yuhang LI
;
Jianlin CHEN
;
Zhiyong YU
;
Zhuoqing QIAO
;
Qinghan WANG
;
Min JIANG
Author Information
1. Department of Hematopoietic Stem Cell Transplantation, Affiliated Hospital to Academy of Military Medical Sciences, Beijing 100071, China
- Publication Type:Journal Article
- Keywords:
Hematologic Diseases;
Allogeneic hematopoietic stem cell transplantation;
Hemorrhage;
Factor Ⅶa,recombinant
- From:
Chinese Journal of Hematology
2017;38(3):216-221
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To analyze the efficacy of recombinant activated factor Ⅶ a (rF Ⅶ a) on hematonosis with moderate or severe bleeding signs.
Methods:Of total 16 cases with rF Ⅶ a treatment from May 2013 to May 2016, 8 cases received allogeneic hematopoietic stem cells transplantation (allo-HSCT) and the other were non-transplantation patients. In two groups, there was no significant difference on rF Ⅶ a usage and dosage. 15 patients with acute graft-versus-host disease (aGVHD) after allo-HSCT were control group (without rF Ⅶ a) .
Results:①The total response rate was 75.0% (6/8) in non-transplantation group and 37.5% (3/8) in transplantation group, respectively. Median interval for hemorrhage stop was 38.5 hours in non-transplantation group and 63.0 hours in transplantation group. The median overall survival (OS) was 201.0 and 29.0 days for non-transplantation group and transplantation group, respectively, and the OS rate was 50.0% (4/8) and 25.0% (2/8) , respectively. The bleeding-related mortality rate was 50.0% (2/4) and 83.3% (5/6) , respectively. ②Of the 16 cases, 9 showed response to rF Ⅶ a treatment and the other 7 cases’bleeding signs did not alleviate. The median OS was 268.0 in 9 cases with response and 24.0 days in 7 cases without response, respectively. ③In patients with intestinal aGVHD complicated with intestinal hemorrhage, the median OS of observation group (n=6) and control group (n=15) were 25.5 days and 20.0 days, respectively.
Conclusion:Patients with hematological diseases, especially patients after allo-HSCT, had high bleeding-related mortality, and rFⅦa therapy had a obvious hemostatic efficacy. The survival rate of patients with response was higher than that of cases without response. The causes of poor hemostasis efficacy of rF Ⅶ a therapy were associated with unsatisfactory control of complications in patients with intestinal bleeding after allo-HSCT.
